Dexcom hosted its Q2 ‘23 earnings (press release; slides) and provided updates across its business. Of note, management highlighted that Dexcom had the highest YOY revenue growth recorded in company history at +26% ($871M) in Q2 ’23. As such, the company has increased its revenue guidance to $3.50-3.55B from $3.40-3.51B. Similar to commentary from Dexcom’s ADA 2023 investor event, management provided updates to the ongoing G7 US and OUS launches and reminded of plans to launch a 15-day sensor for people not on insulin in 2024 (previous FENIX insight). Below, FENIX provides highlights and insights from the call.